Curis (NASDAQ:CRIS) Stock, Quote.Headers.trade-ideas

CURIS INC

Curis

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

News

Penny Stocks

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CRIS

RVMD

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Collapse In Q2

Price Target

Analyst Ratings

CYBR

LBTYA

NOTV

PCTY

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday

Small Cap

Intraday Update

Movers

ANVS

DWAC

ENSC

EVAX

EVER

GETR

GPAK

GYRE

HRTX

KURA

LCID

MMAT

NFLX

NYXH

PRPL

RDHL

RVSN

SAVE

SBEV

SIDU

SMMT

SPRC

SRAD

SWIN

VSME

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes.

BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.

Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Curis Inc

CRISPR Therapeutics AG

CRISM THERAPEUTICS CORP by CRISM THERAPEUTICS CORP

Crism Therapeutics Corp

Offerings

Press Releases

Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement

Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

Earnings

Curis Provides Third Quarter 2024 Business Update

Curis Announces Additional Data from TakeAim Leukemia Study

Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025

Curis Provides Fourth Quarter 2024 Business Update

Curis to Present at Upcoming Healthcare Conference in April

Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

Curis Provides First Quarter 2025 Business Update

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioAtla

BioVie

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Clene

CEL-SCI

Elevation Oncology

GlycoMimetics

HOOKIPA Pharma

Kala Bio

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Longeveron

Leap Therapeutics

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lisata Therapeutics

Nanoviricides

OSR Holdings

Ovid Therapeutics

Passage Bio

Q32 Bio

SAB Biotherapeutics

Vor Biopharma

X4 Pharmaceuticals

HC Wainwright & Co.

Truist Securities

Cantor Fitzgerald

Comments

Curis

Curis (NASDAQ:CRIS) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell